Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
65.67
-0.87 (-1.31%)
Dec 5, 2025, 4:00 PM EST - Market closed
Cytokinetics Stock Forecast
Stock Price Forecast
The 15 analysts with 12-month price forecasts for Cytokinetics stock have an average target of 77.87, with a low estimate of 41 and a high estimate of 120. The average target predicts an increase of 18.58% from the current stock price of 65.67.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Cytokinetics stock from 15 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 5 | 5 | 5 | 5 |
| Buy | 7 | 7 | 9 | 9 | 8 | 8 |
| Hold | 3 | 3 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 14 | 16 | 16 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains $82 → $87 | Buy | Maintains | $82 → $87 | +32.48% | Nov 11, 2025 |
| B. Riley Securities | B. Riley Securities | Strong Buy Reiterates $80 → $90 | Strong Buy | Reiterates | $80 → $90 | +37.05% | Nov 10, 2025 |
| Barclays | Barclays | Buy Maintains $71 → $82 | Buy | Maintains | $71 → $82 | +24.87% | Oct 6, 2025 |
| B of A Securities | B of A Securities | Hold Maintains $52 → $56 | Hold | Maintains | $52 → $56 | -14.73% | Oct 2, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $120 | Strong Buy | Reiterates | $120 | +82.73% | Sep 29, 2025 |
Financial Forecast
Revenue This Year
85.23M
from 18.47M
Increased by 361.33%
Revenue Next Year
140.74M
from 85.23M
Increased by 65.14%
EPS This Year
-6.48
from -5.26
EPS Next Year
-5.76
from -6.48
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 161.5M | 245.7M | ||||
| Avg | 85.2M | 140.7M | ||||
| Low | 68.6M | 53.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 774.3% | 188.3% | ||||
| Avg | 361.3% | 65.1% | ||||
| Low | 271.3% | -37.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -5.20 | -4.70 | ||||
| Avg | -6.48 | -5.76 | ||||
| Low | -7.05 | -6.67 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.